Diabetes and the labor market: The community-wide economic cost in the Lower Rio Grande Valley

Diabetes Care

Volumn 28, Issue 12, 2005, Pages 2945-2947

  Brown III, H Shelton ^a,e   Estrada, Joselita K ^b   Hazarika, Gautam ^c   Bastida, Elena ^d  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b TEXAS A AND M UNIVERSITY AT GALVESTON   (United States)

^c UNIVERSITY OF TEXAS AT BROWNSVILLE   (United States)

^d UNIVERSITY OF TEXAS PAN AMERICAN   (United States)

^e School of Public Health Building   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEALTH CARE COST; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL LITERATURE; POPULATION MODEL; POPULATION RESEARCH; PRODUCTIVITY; COST OF ILLNESS; ECONOMICS; EMPLOYMENT; UNITED STATES;

COST OF ILLNESS; DIABETES MELLITUS; EMPLOYMENT; HUMANS; TEXAS;

EID: 33644818075     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.28.12.2945     Document Type: Article

References (29)

1. Mason JM, Freemantle N, Gibson JM, New JP, the SPLINT Trial: Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial. Diabetes Care 28:40-46, 2005
2. Aoki N, Dunn K, Fukui T, Beck JR, Schull WJ, Li HK: Cost-effectiveness analysis of telemedicine to evaluate diabetic retinopathy in a prison population. Diabetes Care 27:1095-1101, 2004
3. Icks A, Haastert B, Gandjour A, John J, Lowel H, Holle R, Giani G, Rathmann W: Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA survey 2000. Diabetes Care 27:2120-2128, 2004
4. Diabetes Prevention Program Research Group: Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 26:2518-2523, 2003
5. Grover SA, Coupal L, Zowall H, Alexander CM, Weiss TW, Gomes DRJ: How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 24:45-50, 2001
6. Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J: A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 25:303-308, 2002
7. Norris SL,Engelgau MM, Narayan KM: Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care 24:561-587, 2001
8. Ortegon MM, Redekop WK, Niessen LW: Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. Diabetes Care 27:901-907, 2004
9. Brandle M, Davidson MB, Schriger DL, Lorber B, Herman WH: Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care 26:1796-1801, 2003
10. Lairson DR, Pugh JA, Kapadia AS, Lorimor RJ, Jacobson J, Velez R: Cost-effectiveness of alternative methods for diabetic retinopathy screening. Diabetes Care 15:1369-1377, 1992
11. Eddy DM, Schlessinger L: Archimedes: a trial-validated model of diabetes. Diabetes Care 26:3093-3101, 2003
12. American Diabetes Association: Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 24:296-309, 2001
13. American Diabetes Association: Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26:917-932, 2003
14. Batisda E, Pagán JA: The impact of diabetes on adult employment and earnings of Mexican-Americans: findings from a community based study. Health Econ 11:403-413, 2002
15. Kahn M: Health and labor market performance: the case of diabetes. J Labor Econ 16:878-899, 1998
16. Ng YC, Jacobs P, Johnson JA: Productivity losses associated with diabetes in the U.S. Diabetes Care 24:257-261, 2001
17. Lavigne JE, Phelps CE, Mushlin A, Lednar WM: Reductions in individual work productivity associated with type 2 diabetes mellitus. Pharmacoeconomics 21:1123-1134, 2003
18. Brown HS, Pagán JA, Bastida E. The impact of diabetes on employment: genetic IVs in a bivariate probit. Health Econ 14:537-544, 2005
19. Gilmer TP, O'Connor PJ, Rush WA, Crain AL, Whitebird RR, Hanson AM, Solberg LI: Predictors of health care costs in adults with diabetes. Diabetes Care 28:59-64, 2005
20. Joyce AT, Iacoviello JM, Nag S, Sajjan S, Jilinskaia E, Throop D, Pedan S, Ollendorf DA, Alexander CM: End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care 27:2829-2835, 2004
21. Oliva J, Lobo F, Molina B, Monereo S: Direct health care costs of diabetic patients in Spain. Diabetes Care 27:2616-2621, 2004
22. Olveira-Fuster G, Olvera-Marquez P, Carral-Sanlaureano F, Gonzalez-Romero S, Aguilar-Diosdado M, Soriguer-Escofet F: Excess hospitalizations, hospital days, and inpatient costs among people with diabetes in Andalusia, Spain. Diabetes Care 27:1904-1909, 2004
23. Weinstock RS, Hawley G, Repke D, Feuerstein BL, Sawin CT, Pogach LM: Pharmacy costs and glycemic control in the Department of Veterans Affairs. Diabetes Care 27 (Suppl. 2):B74-B81, 2004
24. Maciejewski ML, Maynard C: Diabetes-related utilization and costs for inpatient and outpatient services in the Veterans Administration. Diabetes Care 27 (Suppl. 2):B69-B73, 2004
25. Pagano E, Brunetti M, Tediosi F, Garattini L: Cost of diabetes: a methodological analysis of the literature. Pharmacoeconomics 15:583-595, 1999
26. Bastida E, Cuéllar I, Villa P: Prevalence of diabetes mellitus and related conditions in a South Texas Mexican-American sample. J Community Health Nurs 18:75-83, 2001
27. Hewings GJD: Regional Input-Output Analysis. Hills, CA, Sage Publications, 1985
28. IMPLAN: Implan Professional: Social accounting and impact analysis software (Technical Report). Minneapolis, MN, Minnesota IMPLAN Group, 1999
29. US Census Bureau: American Factfinder (Technical Report). Washington, DC, U.S. Census Bureau, 2005